Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | Updates in ALK+ NSCLC

Ross Camidge • 26 Mar 2020
Lung Cancer Non-Small Cell Lung Cancer

Ross Camidge, MD, PhD, University of Colorado Aurora, Colorado, USA, discusses updates in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) and his thoughts on interpreting the data from clinical trials to better treat patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Ross Camidge

3:21
Hot topics in 2020: lung cancer
Ross Camidge • 26 Mar 2020
4:15
COVID-19 & treating patients with lung cancer
Ross Camidge • 26 Mar 2020
1:30
Efficacy of lorlatinib in NSCLC post-second generation ALK TKI
Ross Camidge • 28 Sep 2019
0:59
Sym015: MET antibody mixture for advanced solid tumors
Ross Camidge • 28 Sep 2019

Related Videos

2:09
Is there a role for radiotherapy in extensive-stage SCLC?
Clive Peedell • 18 Apr 2024
3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
1:03
The benefits of liquid biopsies for lung cancer in the community setting
Deepti Behl • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals